Case Report: Rare Multidrug-Resistant Enterobacter Cloacae Complicated by Invasive Pulmonary Aspergillosis in an Elderly Patient with Advanced Lung Adenocarcinoma Treated with Osimertinib.
Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the standard treatment for EGFR-mutated advanced non-small cell lung cancer (NSCLC).
APA
Zhou M, Shi J, et al. (2026). Case Report: Rare Multidrug-Resistant Enterobacter Cloacae Complicated by Invasive Pulmonary Aspergillosis in an Elderly Patient with Advanced Lung Adenocarcinoma Treated with Osimertinib.. Infection and drug resistance, 19, 598530. https://doi.org/10.2147/IDR.S598530
MLA
Zhou M, et al.. "Case Report: Rare Multidrug-Resistant Enterobacter Cloacae Complicated by Invasive Pulmonary Aspergillosis in an Elderly Patient with Advanced Lung Adenocarcinoma Treated with Osimertinib.." Infection and drug resistance, vol. 19, 2026, pp. 598530.
PMID
41873370
Abstract
Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the standard treatment for EGFR-mutated advanced non-small cell lung cancer (NSCLC). We report a rare case of multidrug-resistant (MDR) Enterobacter cloacae pneumonia complicated by invasive pulmonary aspergillosis (IPA) in a 75-year-old male with lung adenocarcinoma who had been receiving osimertinib for 8 months. Prompt susceptibility-guided therapy with polymyxin B plus tigecycline (for MDR bacteria) and voriconazole (for aspergillosis) achieved complete resolution, highlighting the importance of rapid microbiological diagnosis and targeted antimicrobials in this vulnerable population.
같은 제1저자의 인용 많은 논문 (5)
- Mitochondria in T‑cell tumor immunity and tumor therapies targeting mitochondria (Review).
- Evaluation of therapeutic efficacy in hepatocellular carcinoma ablation based on CT radiomics and deep learning multimodal models.
- Decoding the metabolic-immune axis for novel therapeutics in bladder cancer.
- Clinical-Inspired Design of Self-Assembled Albumin-CeO Nanozymes for Oxygen-Self-Sufficient and Targeted Sonodynamic-Chemotherapy in Triple-Negative Breast Cancer.
- Microglial PD-1/PD-L1 axis in CNS demyelinating diseases: a dual immunoregulatory perspective.